Source: GlobalData
Endometriosis diagnosed prevalent cases in women to reach 2.8 million across 7MM in 2034, forecasts GlobalData
Posted in Pharma
The diagnosed prevalent cases of endometriosis among women ages 12–54 years in the seven major markets (7MM*) are set to register an annual growth rate (AGR) of 0.09% from 2.77 million in 2024 to 2.8 million in 2034, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Endometriosis – Epidemiology Forecast to 2034,” reveals that the US will have the highest number of diagnosed prevalent cases of endometriosis among the 7MM at 1.51 million cases, whereas Japan will have the lowest number at 0.09 million cases in 2034.
Antara Bhattacharya, Associate Project Manager, Epidemiology team at GlobalData, comments: “In 2024, women in ages 30–54 years accounted for almost 92% of the diagnosed prevalent cases of endometriosis in the 7MM, while younger women in ages 12–29 years accounted for approximately 8% of the cases.”
GlobalData estimates that in 2024, approximately 64% of diagnosed prevalent cases of endometriosis in the 7MM were laparoscopy confirmed, whereas 36% of diagnosed prevalent cases of endometriosis suspected cases. In 2024, approximately 28% of diagnosed prevalent cases of endometriosis were in stage IV, whereas 22% of diagnosed prevalent cases of endometriosis were in stage I.
In the 7MM, approximately 44% of diagnosed prevalent cases of endometriosis were superficial peritoneal endometriosis, whereas 19% of diagnosed prevalent cases were deep infiltrating endometriosis in 2024. Approximately 44% of diagnosed prevalent cases of endometriosis were with dysmenorrhea.
Bhattacharya concludes: “Endometriosis significantly impacts quality of life among women of reproductive age due to pain, fatigue, and other symptoms that can affect daily activities, work productivity, and relationships. This may further lead to psychological consequences. Diagnostic delay, limited capacity of health systems, and sub-optimal access to specialized surgery such as laparoscopy further exacerbate the condition, since prompt access to available treatment methods, including non-steroidal analgesics, progestin-based contraceptives, is often not achieved.
“Addressing endometriosis through various treatments and supportive care can help improve the quality of life for those affected. Additionally, capacity development of primary healthcare providers is essential to initiate treatment for patients who could benefit from medical symptomatic management.”
*7MM: The US, 5EU (France, Germany, Italy, Spain, the UK), and Japan.